FDA Warning Letter to Nihon Kohden Digital Health Solutions, LLC (2026-06-12) — Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)
Letter issued · posted to fda.gov .
Subject as published: Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)
TL;DR
In short: The FDA's Center for Devices and Radiological Health issued a warning letter to Nihon Kohden Digital Health Solutions, LLC (CMS #727803, June 12, 2026) regarding the Next Generation NetKonnect software device, a patient physiological monitor with arrhythmia detection. The agency determined the device is adulterated and misbranded because: (1) a software modification adding a Silence Alarms function implemented October 22, 2022 constitutes a control mechanism change requiring a new 510(k) submission that was never filed; and (2) the device's current labeling claims "device-agnostic compatibility" with non-Nihon Kohden devices, which exceeds the scope of the original K220989 clearance (July 29, 2022) that authorized only Nihon Kohden device inputs. The FDA stated these changes could result in missed alarms for life-threatening conditions and interoperability failures causing diagnostic delays or misdiagnosis, and warned that failure to address violations may result in seizure, injunction, or civil penalties.
Argus analysis
# FDA Warning Letter Analysis: Nihon Kohden Digital Health Solutions, LLC
**Company and Findings**
Nihon Kohden Digital Health Solutions, LLC, based in Irvine, California, received a Warning Letter from FDA's Center for Devices and Radiological Health on June 12, 2026, following a two-day inspection in February 2026. The company manufactures the Next Generation NetKonnect (NGNK) software, a patient physiological monitor with arrhythmia detection and ST-segment measurement capabilities. FDA determined the device is being distributed without required premarket authorization and contains unapproved modifications that expand its intended use beyond what was originally cleared.
**Regulatory Citations and Implications**
The violations cite 21 U.S.C. § 351(f)(1)(B) for adulteration—the device lacks either an approved Premarket Approval (PMA) application or valid 510(k) clearance—and 21 U.S.C. § 352(o) for misbranding due to failure to submit required premarket notification. The specific product is classified as a Class II device under 21 CFR 870.1025. FDA identified two substantive issues: a October 2022 software change adding a "Silence Alarms" function that represents a control mechanism modification requiring new 510(k) submission, and expansion to "device-agnostic compatibility" (supporting non-Nihon Kohden inputs) that exceeds the scope of the 2022 K-series clearance. Both changes potentially introduce patient safety risks including missed critical alarms and interoperability failures.
**Response Timeline and Monitoring**
Nihon Kohden must submit a written response within fifteen business days detailing corrective actions, systemic root causes, and implementation timelines. Compliance officers in cardiac monitoring should monitor whether the company pursues amended 510(k) submissions, implements design controls to prevent similar untracked modifications, or faces escalated enforcement (seizure, injunction, or civil penalties). FDA's tone suggests systemic quality management deficiencies warrant close attention to any subsequent product submissions or inspection outcomes.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Medical device Warning Letters typically combine QSR observations (21 CFR Part 820) with adulteration (21 USC 351) or misbranding (21 USC 352). Post-market surveillance and MDR reporting (21 CFR Part 803) are recurring subjects.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Nihon Kohden Digital Health Solutions, LLC MARCS-CMS 727803 — June 12, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Medical Devices Recipient: Recipient Name Harsh Dharwad Recipient Title President and Chief Executive Officer Nihon Kohden Digital Health Solutions, LLC 14 Bunsen Irvine , CA 92618 United States (b)(6), (b)(7)(C) Issuing Office: Center for Devices and Radiological Health United States WARNING LETTER CMS #727803 June 12, 2026 Dear Mr. Dharwad: During an inspection of your firm located in Irvine, CA from February 23, 2026 through February 24, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Next Generation NetKonnect software device, which is a Patient Physiological Monitor device with Arrhythmia detector and alarm (including ST-segment measurement and alarm). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Unapproved Device Violation(s) Our inspection revealed that your Next Generation NetKonnect (NGNK) software device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)(1)(i)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/default.htm. The FDA will evaluate the information that your firm submits and respond as appropriate. Specifically, your firm’s Next Generation NetKonnect software devices are class II devices regulated under 21 CFR 870.1025 - Arrhythmia detector and alarm (including ST-segment measurement and alarm). Your device was most recently cleared as K220989 on July 29, 2022. On October 22, 2022, you implemented a software change to the device which included the ability to enable a Silenc…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Medical device warning letter?
- Medical device Warning Letters typically combine QSR observations (21 CFR Part 820) with adulteration (21 USC 351) or misbranding (21 USC 352). Post-market surveillance and MDR reporting (21 CFR Part 803) are recurring subjects.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Nihon Kohden Digital Health Solutions, LLC had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Nihon Kohden Digital Health Solutions, LLC as of 2026-07-14. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Warning Letter to Nihon Kohden Digital Health Solutions, LLC (2026-06-12) — Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k). Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-nihon-kohden-digital-health-solutions-llc-2026-06-12-medical-device
"FDA Warning Letter to Nihon Kohden Digital Health Solutions, LLC (2026-06-12) — Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-nihon-kohden-digital-health-solutions-llc-2026-06-12-medical-device.
Argus HQ Research. "FDA Warning Letter to Nihon Kohden Digital Health Solutions, LLC (2026-06-12) — Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)." Digital Empire LLC. Accessed July 16, 2026. https://argushq.ai/fda/warning-letter/fda-wl-nihon-kohden-digital-health-solutions-llc-2026-06-12-medical-device.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_nihon_kohden_digital_health_solutions_llc_2026_06_12_medical_device_2026,
title = {FDA Warning Letter to Nihon Kohden Digital Health Solutions, LLC (2026-06-12) — Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-nihon-kohden-digital-health-solutions-llc-2026-06-12-medical-device},
note = {Accessed: July 16, 2026}
}